Your session is about to expire
← Back to Search
Dostarlimab for Colon Cancer (AZUR-2 Trial)
AZUR-2 Trial Summary
This trial tests a new drug to see if it can help treat colon cancer in people with a certain gene defect.
AZUR-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 18 Patients • NCT04409002AZUR-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had major surgery or serious injuries in the last 28 days.My cancer has spread to distant parts of my body.My tumor is causing severe bowel problems needing urgent surgery.I have an untreated colon cancer diagnosis.My tumor is identified as dMMR or MSI-H.I have a history of lung inflammation or scarring.I have had a stem cell or organ transplant.I have severe allergies to certain antibodies or components in cancer treatments.My colon cancer is at an advanced stage but can still be surgically removed.I am not on any other cancer treatments or experimental drugs.I have had treatment (like chemo, immunotherapy, or surgery) for colon cancer.I have liver problems, including cirrhosis or unstable liver disease.
- Group 1: Dostarlimab
- Group 2: Standard of Care (SOC)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies in this clinical investigation for prospective participants?
"Data hosted on clinicaltrials.gov reflects that this trial is presently seeking out participants. It was initially posted online on August 1st 2023 and the details were most recently revised two weeks later, on August 21st 2023."
Does the Food and Drug Administration recognize Dostarlimab as a safe treatment?
"As this is a Phase 3 trial, with evidence of efficacy and multiple rounds of safety data collected, Dostarlimab was rated as safe with a score of 3."
In how many health care centers is this clinical experiment conducted?
"This medical investigation is taking place in 159 sites, with concentrations of locations found in Leuven, Liège and Roeselare. It would be prudent for enrollees to choose a local centre so that the travelling requirements are kept at bay."
How many individuals have been recruited to participate in this trial thus far?
"Affirmative. According to information available on clinicaltrials.gov, this medicinal exploration was initially made public on August 1st 2023 and has been recently amended on the 21st of that same month. Currently, 711 participants are required for the study which is being conducted across 159 various venues."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger